April 30, 2018
Helsinn Investment Fund, Bio Capital Impact Fund and Windham Venture Partners Join a Leading Investor Syndicate to Support the Commercialization Efforts Of NovellusDx
JERUSALEM–(BUSINESS WIRE)–NovellusDx, the leader in functional genomics, today announced it has completed an equity financing of $6 million. The financing round is with the participation of Helsinn Investment Fund S.A. … Continued